Our stockholders approved the FactSet Research Systems Inc. 2025 Omnibus Incentive Plan (the "Omnibus Plan") on December 18, 2025. The Omnibus Plan replaced both the FactSet Research Systems Inc. Stock Option and Award Plan, as Amended and Restated and the FactSet Research Systems Inc. Non-Employee Directors’ Stock Option and Award Plan, as Amended and Restated.

On September 1, 2025, the FactSet Research Systems Inc. 2025 Employee Stock Purchase Plan replaced the FactSet Research Systems Inc. 2008 Employee Stock Purchase Plan, as Amended and Restated.

Our stock-based compensation expense consists of: (i) stock options, (ii) PSOs issued to our CEO, (iii) RSUs, (iv) PSUs, and (v) common stock purchased by eligible employees under our ESPP.

There were no stock-based compensation costs capitalized during fiscal 2024 through fiscal 2026. As of August 31, 2026, $147.2 million of total unrecognized stock-based compensation expense related to non-vested stock-based awards is expected to be recognized over the remaining weighted average vesting period of 2.6 years.


	Number Outstanding (thousands)	Weighted Average Exercise Price Per Share		Aggregate Intrinsic Value (millions)(1)		Weighted Average Remaining Contractual Life (years)












Outstanding as of August 31, 2025	1,685	$	347.50
Granted – employees	233	$	261.59
Granted – CEO PSOs(2)	298	$	295.63
Granted – non-employee directors(3)	12	$	289.68
Exercised(4)	(123)	$	185.34
Forfeited	(190)	$	333.71
Outstanding as of August 31, 2026(5)	1,915	$	340.43	$	51.0	5.8
Options vested and exercisable as of August 31, 2026	1,007	$	332.25	$	34.2	3.9
Options expected to vest as of August 31, 2026	805	$	352.83	$	14.4	7.9

(1)The aggregate intrinsic value represents the difference between our closing stock price as of August 31, 2026 of $313.55 and the exercise price, multiplied by the number of options exercisable as of that date.

(2)Reflects a one-time grant of PSOs to our CEO. Refer to CEO Performance Stock Option Awards within this section below, for more information.

(3)The non-employee directors weighted average grant date fair value of stock options granted during fiscal 2026, 2025 and 2024 was $69.88, $144.90 and $132.78, respectively.

(4)The total pre-tax intrinsic value of stock options exercised during fiscal 2026, 2025 and 2024 was $9.2 million, $66.5 million and $89.5 million, respectively.

(5)As of August 31, 2026, 908,564 of our total outstanding stock options were unvested, resulting in unamortized stock-based compensation expense of $52.5 million that is expected to be recognized over the remaining weighted average vesting period of 2.4 years.

During fiscal 2026, 2025 and 2024, the total fair value of stock options vested was $25.1 million, $23.2 million and $20.5 million, respectively.

Our annual grant of employee stock options during the first quarter of each fiscal year makes up the majority of our employee stock options granted in each fiscal year. The following table presents the weighted average inputs used in the lattice model to estimate the grant-date fair value of the employee stock options granted:


	2026		2025		2024
Stock options granted(1)	232,567		203,114		243,379
Risk-free interest rate	3.61% - 4.48%		4.31% - 4.87%		3.78% - 5.53%

Expected life (years)	6.4		6.6		6.6

Expected volatility	27% - 31%		23% - 25%		19% - 25%

Dividend yield	1.38	%	0.95	%	0.90	%
Weighted Average Grant Date Fair Value	$75.40		$133.21		$132.59

(1) Includes the annual employee grant on November 3, 2025, November 1, 2024 and November 1, 2023 of 213,811, 200,693 and 242,371 stock options, respectively. The majority of the stock options granted during fiscal 2026, including the annual employee grant, vest 25% annually on the anniversary date of the grant and are fully vested after four years, expiring ten years from the date of grant. The majority of the stock options granted during fiscal 2025 and 2024, including the annual employee grants, vest 20% annually on the anniversary date of the grant and are fully vested after five years, expiring ten years from the date of grant.

On September 22, 2025, we granted PSOs to our CEO, as part of his May 28, 2025 employment agreement. The PSOs vest if, during the performance period ending on the fifth anniversary of the grant date, our common stock achieves a 30-day trailing volume-weighted average price ("VWAP") equal to or greater than 150% of the 30-day trailing VWAP ending on the grant date. Options are not exercisable before the third anniversary of the grant date. These options expire 10 years from the grant date. We used the Monte Carlo model to estimate the grant date fair value of the September 22, 2025 CEO PSO grant. The following table presents the grant information and model assumptions:


	CEO PSO Grant
Employee Grant Details	September 22, 2025
Stock options granted	297,902
Grant Date Fair Value	$73.85

Assumptions
Risk-free interest rate	4.08	%


Expected volatility	24.72	%

Dividend yield	0.90	%
Expected life (years)	5.00


(in thousands, except per award data)	Number Outstanding	Weighted Average Grant Date Fair Value Per Award












Balance at August 31, 2025	293	$	429.19
Granted – employee Restricted Stock Awards(1)(2)	326	$	257.12

Granted – non-employee directors RSUs(2)	5	$	285.16
Vested(3)	(72)	$	419.81
Forfeited	(43)	$	370.75
Outstanding as of August 31, 2026(4)	509	$	323.63

(2)The employee Restricted Stock Awards weighted average grant date fair value granted during fiscal 2026, 2025 and 2024 was $257.12, $444.30 and $423.57, respectively. The non-employee directors RSUs weighted average grant date fair value granted during fiscal 2026, 2025 and 2024 was $285.16, $449.72 and $458.23, respectively.

(3)During fiscal 2026, 2025 and 2024, the total fair value of RSUs vested was $24.8 million, $21.7 million and $17.7 million, respectively, and for PSUs vested was $5.8 million, $14.4 million and $13.6 million, respectively.

(4)As of August 31, 2026, 508,581 Restricted Stock Awards were unvested and outstanding, which resulted in unamortized stock-based compensation expense of $94.7 million that is expected to be recognized over the remaining weighted average vesting period of 2.6 years.

Our annual grant of employee Restricted Stock Awards during the first quarter of each fiscal year makes up the majority of our employee Restricted Stock Awards granted each fiscal year. These awards entitle the holders to shares of common stock as the Restricted Stock Awards vest. For unvested Restricted Stock Awards, holders are not entitled to dividends declared on the underlying shares. In accordance with the Omnibus Plan, Restricted Stock Awards granted or canceled/forfeited is equivalent to 2.5 shares deducted from or added back to, respectively, the aggregate number of stock-based awards available for grant.

The majority of the RSUs granted during fiscal 2026 vest 25% annually on the anniversary date of the grant and are fully vested after four years, while the majority of the RSUs granted in fiscal 2025 and 2024 vest 20% annually over five years. The majority of the PSUs granted cliff vest on the third anniversary of the grant date. The ultimate number of common shares that may be earned pursuant to our PSU awards depends on the level of our achievement of stated financial performance objectives. The achievement range was 0% to 200% for the November 3, 2025, November 1, 2024 and November 1, 2023 annual grants.